Log in

NASDAQ:RPRX - Repros Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume251,774 shs
Average Volume473,590 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:RPRX



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive RPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

Repros Therapeutics (NASDAQ:RPRX) Frequently Asked Questions

What is Repros Therapeutics' stock symbol?

Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."

How were Repros Therapeutics' earnings last quarter?

Repros Therapeutics Inc (NASDAQ:RPRX) released its quarterly earnings results on Monday, November, 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.24. The biotechnology company had revenue of $0.30 million for the quarter. View Repros Therapeutics' Earnings History.

Has Repros Therapeutics been receiving favorable news coverage?

News headlines about RPRX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Repros Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Repros Therapeutics.

Who are some of Repros Therapeutics' key competitors?

What other stocks do shareholders of Repros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repros Therapeutics investors own include Twitter (TWTR), Bausch Health Companies (BHC), Relypsa (RLYP), AEterna Zentaris (AEZS), Intercept Pharmaceuticals (ICPT), Verastem (VSTM), Achillion Pharmaceuticals (ACHN), Sarepta Therapeutics (SRPT), Merrimack Pharmaceuticals (MACK) and XOMA (XOMA).

Who are Repros Therapeutics' key executives?

Repros Therapeutics' management team includes the folowing people:
  • Patrick P. Fourteau, Chairman of the Board (Age 69)
  • Larry M Dillaha M.D., President, Chief Executive Officer, Director (Age 53)
  • Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary (Age 58)
  • Joachim F. Wernicke, Chief Medical Officer (Age 68)
  • Daniel F. Cain, Independent Director (Age 70)
  • Nola E. Masterson, Independent Director (Age 69)
  • Saira Ramasastry, Independent Director (Age 40)
  • Michael G. Wyllie Ph.D., Independent Director (Age 65)

What is Repros Therapeutics' official website?

The official website for Repros Therapeutics is http://www.zonagen.com/.

How can I contact Repros Therapeutics?

Repros Therapeutics' mailing address is 2408 Timberloch Pl Ste B7, THE WOODLANDS, TX 77380-1021, United States. The biotechnology company can be reached via phone at +1-281-7193400 or via email at [email protected]

MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  489
MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe RPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel